Targeted degradation of CD147 proteins in melanoma.

[1]  Philip P. Chamberlain,et al.  Development of targeted protein degradation therapeutics , 2019, Nature Chemical Biology.

[2]  M. Mori,et al.  Signal Transducer and Activator of Transcription Protein 3 (STAT3): an Update on its Direct Inhibitors as Promising Anticancer Agents. , 2019, Current medicinal chemistry.

[3]  Bin Yang,et al.  Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. , 2019, Bioorganic & medicinal chemistry letters.

[4]  A. Vaisi-Raygani,et al.  CD147 as an apoptosis regulator in spermatogenesis: deciphering its association with matrix metalloproteinases’ pathway , 2019, Molecular Biology Reports.

[5]  David M. Wilson,et al.  Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. , 2018, ACS chemical biology.

[6]  Xiaowei Xu,et al.  Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression , 2018, International journal of oncology.

[7]  Liwu Fu,et al.  Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs , 2018, EBioMedicine.

[8]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[9]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[10]  Youli Xiao,et al.  Chemical proteomics reveal CD147 as a functional target of pseudolaric acid B in human cancer cells. , 2017, Chemical communications.

[11]  Xiang Chen,et al.  Targeting CD147 is a Novel Strategy for Antitumor Therapy. , 2017, Current pharmaceutical design.

[12]  C. Crews,et al.  Targeted protein degradation by PROTACs☆ , 2017, Pharmacology & therapeutics.

[13]  C. Crews,et al.  Waste disposal—An attractive strategy for cancer therapy , 2017, Science.

[14]  M. Naito,et al.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)* , 2017, The Journal of Biological Chemistry.

[15]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[16]  V. Holubekova,et al.  Determination of malignant potential of cervical intraepithelial neoplasia , 2016, Tumor Biology.

[17]  Eunhwa Ko,et al.  Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. , 2016, Angewandte Chemie.

[18]  T. Muramatsu.  Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners , 2015, Journal of biochemistry.

[19]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[20]  X. Chen,et al.  CD147 interacts with NDUFS6 in regulating mitochondrial complex I activity and the mitochondrial apoptotic pathway in human malignant melanoma cells. , 2014, Current molecular medicine.

[21]  Bin Wang,et al.  A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway , 2014, Clinical & Experimental Metastasis.

[22]  Yang Zhang,et al.  A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. , 2014, Cancer research.

[23]  T. Lawrence,et al.  HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s , 2013, Clinical Cancer Research.

[24]  Wen-bin Tang,et al.  A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells. , 2013, Cancer letters.

[25]  H. Xie,et al.  Propranolol induces apoptosis of human umbilical vein endothelial cells through downregulation of CD147 , 2012, The British journal of dermatology.

[26]  S. Qiu,et al.  Interaction of pseudolaric acid B with the colchicine site of tubulin. , 2012, Biochemical pharmacology.

[27]  Hannes Stockinger,et al.  Cancer-related issues of CD147. , 2010, Cancer genomics & proteomics.

[28]  T. Kanekura,et al.  CD147/basigin promotes progression of malignant melanoma and other cancers. , 2010, Journal of dermatological science.

[29]  Xiang Chen,et al.  A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. , 2009, Cancer letters.

[30]  Jing Lin,et al.  A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. , 2006, Cancer research.

[31]  Jian Ding,et al.  Pseudolarix Acid B, a New Tubulin-Binding Agent, Inhibits Angiogenesis by Interacting with a Novel Binding Site on Tubulin , 2006, Molecular Pharmacology.

[32]  L. Chow,et al.  Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivo , 2005, Clinical Cancer Research.

[33]  Yi Tang,et al.  Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.

[34]  T. Hoang‐Xuan,et al.  EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. , 2005, Biochimie.

[35]  T. Kanekura,et al.  Basigin (cd147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts , 2002, International journal of cancer.

[36]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[37]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[38]  Y. Okada,et al.  Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. , 2000, Cancer letters.

[39]  J. Regezi,et al.  Expression of EMMPRIN by oral squamous cell carcinoma , 2000 .

[40]  M. Polette,et al.  Expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and the Matrix Metalloproteinase-2 in Bronchopulmonary and Breast Lesions , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.